Invasion of neighboring tissues (that is, trachea, aorta,
|
|
- Giles Nash
- 6 years ago
- Views:
Transcription
1 Factors Predictive of Complete Resection of Operable Esophageal Cancer: A Prospective Study Christophe Mariette, MD, Laetitia Finzi, MD, Sylvain Fabre, MD, Jean-Michel Balon, MD, Isabelle Van Seuningen, PhD, and Jean-Pierre J. Triboulet, MD Service de Chirurgie Digestive et Générale Hôpital Claude Huriez and Unité INSERM 560 CHRU, Lille, France Background. Esophagectomy remains a standard treatment for patients with resectable esophageal cancer, but the 5-year survival is only 20% to 25%. After complete resection survival is significantly longer than after incomplete resection with microscopic or macroscopic penetration. The purpose of this study was to prospectively identify the factors predictive of complete resection of operable esophageal cancers. Methods. Betwen January 1995 and January 2002, 372 patients with esophageal cancer underwent surgery with curative intent. Complete resection was performed in 304 patients (81.7%), incomplete resection with microscopic penetration in 28 (7.5%), and incomplete resection with macroscopic penetration in 40 (10.8%). Univariate and multivariate analysis included 16 preoperative and operative factors. Results. Factors predictive of complete resection were absence of any modification of the esophageal axis on the barium swallow (p 0.019) and a partial or complete Invasion of neighboring tissues (that is, trachea, aorta, lung, pericardium) is common in cancer of the esophagus and is caused by anatomic proximity and lack of a protective serosa. Complete surgical resection is one of the most important prognostic factors [1 4]. Therefore it is fundamental to establish a precise assessment of tumor extension to avoid incomplete surgical resection and establish an appropriate therapeutic strategy. Despite recent advances in imaging techniques, the rate of incomplete resection has varied from 19.2% to 64.0% depending on the series [5]. In a retrospective study [6] we showed that complete resection of esophageal cancer was predictable. The purpose of this study was to prospectively identify factors predictive of complete resection (R0), as defined in the Union Internacional Contra la Cancrum (UICC) 1993 classification of operable esophageal cancer, to determine the appropriate pre-therapeutic workup for defining a population likely to benefit from surgical resection in terms of survival. Patients and Methods Patients Between January 1995 and January 2002, 372 patients (mean age, 58.1 years; standard deviation [sd], 9.8; range, Accepted for publication Jan 14, Address reprint requests to Dr Triboulet, Service de Chirurgie Digestive et Générale Hôpital, Claude Huriez CHRU, Place de Verdun, Lille Cedex 59037, France; jp-triboulet@chru-lille.fr. response to preoperative radiochemotherapy (p 0.042). Three groups of patients were identified: group 1 had no deviation of the axis on the barium swallow (n 253); group 2 had deviation of the axis on the barium swallow and partial or complete response to radiochemotherapy (n 66); and group 3 had deviation of the axis on the barium swallow and no response to radiochemotherapy or no preoperative treatment (n 53). Rates of complete resection were 90.1%, 74.2%, and 50.9%, and 5-year actuarial survivals were 46%, 37%, and 0%, respectively (p < 0.001). Conclusions. Complete resection of esophageal cancer is predictable. Deviation axis on the barium swallow and morphologic response to neoadjuvant radiochemotherapy are variables available for all patients at onset of therapeutic management. (Ann Thorac Surg 2003;75:1720 6) 2003 by The Society of Thoracic Surgeons 31 to 78 years) with cancer of the cervical or thoracic esophagus underwent surgery with curative intent in our digestive surgical unit of the Claude Huriez university hospital (Lille, France). The hospital files of these patients were prospectively noted. Patients were considered to be operable with resectable esophageal cancer after a complete pre-therapeutic workup (including physical examination; standard laboratory tests; ear, nose, and throat examination; panendoscopy under general anesthesia for squamous cell tumors; digestive fibroscopy and esogastroduodenal barium study; bronchial fibroscopy with biopsies; ultrasound exploration of the cervical and abdominal areas; computed tomographic (CT) scan of the thorax, mediastinum and abdomen; and endoscopic ultrasound). Criteria for nonresecability were adherence to the aorta ( 90 ), invasion of the pericardium, diaphragm, pleura, trachea-bronchi, azygos vein, recurrent nerve, tumor diameter ( 4 cm), celiac or subclavian lymph node enlargement, and visceral metastasis. Criteria for nonoperability were cirrhosis (any stage) associated with portal hypertension, respiratory failure, forced expiratory volume ( 1,000 ml/s), weight loss more than 20%, heart failure (New York Heart Association functional class III to IV). Surgical Approach The detailed resection techniques have been described elsewhere [1]. Surgical resection consisted of a transthoracic esophagectomy for tumor of the middle-third or 2003 by The Society of Thoracic Surgeons /03/$30.00 Published by Elsevier Inc PII S (03)
2 Ann Thorac Surg MARIETTE ET AL 2003;75: ESOPHAGEAL CANCER RESECTION lower-third of the esophagus, completed with a cervical incision for anastomosis in case of tumor of the upperthird of the thoracic esophagus. The surgical approach included an abdominal lymphadenectomy and an extended en bloc mediastinal lymphadenectomy (two-field lymphadenectomy). No cervical lymphadenectomy was undertaken. Abdominal lymphadenectomy comprised en bloc removal of all lymphatic tissue in the lower posterior mediastinum, in the left and right pericardial regions, along the lesser curve, and along the left gastric artery. A meticulous lymphadenectomy of the peritracheal, carinal, and left and right bronchial nodes was performed followed by en bloc resection of the thoracic duct together with the periaortic nodes. The nodes in the aortopulmonary window were removed but routinely a full dissection of the left recurrent laryngeal nerve chain was not carried out. For patients with respiratory insufficiency and limited tumor of the esophagus, a subtotal esophagectomy without thoracotomy was realized, with only an abdominal and mediastinal inferior lymphadenectomy. The esophagus was replaced by the stomach in 96.8% of patients, excepting patients with a history of gastric surgery or who required composite plasty for cancer of the remaining esophagus. Histopathological Analysis Assessment of the Removed Specimen and Lymph Nodes All nodal material was dissected separately from the specimen at the end of the procedure by the surgeon, and the resection specimen was assessed by an experienced pathologist according to the ptnm classification [7]. Squamous cell carcinoma (SCC) was found in 283 patients, adenocarcinoma in 79, and other tumoral types in 10. Tumors were well or moderately differentiated in 251 patients and poorly or undifferentiated in 121 patients. On histopathologic assessment of the 372 resected specimens, the distribution of pt and pn categories was as follows: the lesion was restricted to mucosa in 58 patients, submucosa in 88 patients, and muscularis propria in 51 patients; the lesion had invaded the adventitia in 152 patients (57% of these were adenocarcinoma) and the neighboring structures in 23 patients; and lymph node metastases were found in 180 patients. Tumoral stages were as follows: esophageal cancer stage I (ptispt1n0m0), n 109; stage IIA (pt2-t3n0m0), n 76; stage IIB (pt1-t2n1m0), n 60; stage III (pt3n1 or pt4nxm0], n 127. A mean (sd) of 19.8 lymph nodes (10.9) (range, 2 to 56) was dissected from each specimen by the surgeon and pathologist. The mean (sd) number of histopathologically positive lymph nodes was 1.9 (3.2) (range, 0 to 25). Variables Studied The preoperative and operative variables presented in Table 1 were used to search for factors predictive of complete resection. Tumor localization was determined by endoscopy and expressed as the distance from the upper pole of the tumor to the mandibular arcade (distance T-MA). A threshold distance of 25 cm was retained because this stratification level has been identified as a prognostic factor in esophageal cancer [6]. Siewert type 1 cancers of the cardia were included in the analysis. Patients with tumors of the hypopharynx or of the esophagus involving the upper esophageal sphincter were excluded. Deviation of the esophageal axis corresponded to a deviation from a virtual axis drawn through the middle of the esophageal lumen over its entire height (Fig 1). Local tumor extension was assessed before treatment by measuring the tumor height on the barium swallow ( 10 cm or 10 cm) and the maximal diameter of the tumor visualized on the CT scan, in accordance with the Wurtz classification as modified [2]. Endoscopic ultrasonography was used to assess the integrity of the different layers of the esophageal wall. Involvement of coronal and lesser curvature stomachal, pericardial, lateral esophageal, lateral aortic, intertracheobronchial, intertracheocaval, and subclavian nodes was considered to be regional extension. Invasion of the celiac or supraclavian nodes was considered to be metastatic. Node size was measured on the CT scan; nodes were considered invaded when the greater diameter measured greater than or equal to 10 mm. Endoscopic ultrasonography was used to study the size, sphericity, echostructure, and contour of the nodes that were suspected to be metastatic when well-delimited and round, with a homogeneous echostructure and a greater diameter ( 10 mm). Neoadjuvant radiochemotherapy was proposed for locally advanced tumors or within the framework of therapeutic protocols. The following morphologic criteria were used to assess response to neoadjuvant radiochemotherapy: Complete response: absence of identifiable tumor on plain roentgenograms or CT scan. Endoscopy was not performed routinely in all patients as negative biopsies can not rule out residual tumor fragments. Partial response: greater than or equal to 50% reduction in tumor size determined as the product of the largest dimensions of formations with two measurable dimensions or less than or equal to 30% reduction of the dimension measured for formations with one measurable dimension, without development of a new formation during treatment. Stability: less than 50% reduction or less than 25% progression of tumors with two measurable dimensions. Progression: more than 25% progression of measurable tumors or development of a new tumor Among the 174 patients who had preoperative radiochemotherapy, 104 (59.8%) exhibited morphologic partial response and 45 (25.9%) exhibited complete response. Postoperative radiochemotherapy or chemotherapy, or both, were proposed in all patients with incomplete resection with microscopic penetration (R1) or incomplete resection with macroscopic penetration (R2). Statistical Analysis The survival status of patients was ascertained in July Follow-up was complete for all 372 patients. Data are shown as prevalence or mean (standard deviation). Comparison of continuous data between groups was determined by the Student s t test and for ordinal data by GENERAL THORACIC
3 1722 MARIETTE ET AL Ann Thorac Surg ESOPHAGEAL CANCER RESECTION 2003;75: Table 1. Preoperative and Operative Parameters Used to Search for Factors Predictive of Complete Resection (RO) Variables N 372 % Age 60 yrs yrs Gender Male Female Malnutrition a No Yes Dysphagia No Yes Distance T-MA 25 cm cm Esophageal deviation on barium swallow No Yes Tumor height on barium swallow 10 cm cm Tumor diameter on CT 30 cm mm Lymph node invasion CT No Yes T (endoscopic ltrasonography (n 249) us T1 T us T N (endoscopic ltrasonography) (n 249) us No us N Histological type Squamous cell Adenocarcinoma Other Tumor differentiation Moderate to well Poor or none Treatment Surgery alone Neoadjuvant radiochemotherapy Response to radiochemotherapy Complete or partial Stability or progression Type of resection With thoracotomy Without thoracotomy a 10% weight loss, distance T-MA: distance between the upper pole of the tumor and the mandibular arcades. the 2 test or Fischer s exact test when appropriate. In analyzing survival time, we used the Statistical Package for Social Sciences (SPSS, Chicago, IL). The survival function has been estimated by the actuarial method without excluding the postoperative deaths. The log rank test was used for comparison of survival curves. To determine which of many covariates was the most significant risk factor regarding quality of surgical resection, we used the stepwise logistic regression model, adjusting all the covariates simultaneously. The 0.1 level was defined for entry into the model. Groups with different risks were identified using a stepwise procedure starting with the two most significant variables from the multivariate analysis. The model retained included two variables known at the time of diagnosis that would be potentially useful for determining resectability. Survival curves were compared between the different subgroups thus defined to establish sets of groups with significantly different risk patterns. Differences in the rate of R0 resection between the defined groups were analyzed with the 2 test. Differences were considered to be significant at 5% alpha risk. Results Postoperative Mortality and Morbidity The in-hospital mortality rate was 4.3% (n 16). Significant complications occurred in 142 patients (38.2%).
4 Ann Thorac Surg MARIETTE ET AL 2003;75: ESOPHAGEAL CANCER RESECTION 1723 interval was 27.9 months (20.8) (range, 6 to 91 months), with a median follow-up of 22 months. Median survival for the overall population was 40 months. Overall survival at 1, 3, and 5 years was 84%, 56%, and 40%, respectively. Median survival was 54.9 months in the R0 group and 10.8 months in the R1 and R2 group. The 1, 3, and 5-year survival rates were 93%, 65%, and 47% in the R0 group and 42%, 12%, and 4% in the R1 and R2 group, respectively (p 0.001). GENERAL THORACIC Univariate Analysis The results of the univariate analysis are presented in Table 2. Eight variables were found to be statistically related to the R0 resection group: (1) absence of dysphagia, (2) absence of esophageal deviation on barium swallow, (3) tumor height ( 10 cm), (4) tumor diameter ( 30 mm on CT scan), (5) tumor restricted to the muscularis propria at endoscopic ultrasonography, (6) no evidence of lymph node invasion on CT scan, (7) no evidence of lymph node invasion on endoscopic ultrasonography, and (8) total or partial response to preoperative radiochemotherapy. Multivariate Analysis Multivariate analysis (Table 3) identified two preoperative variables predictive of R0 surgical resection: (1) esophageal deviation on barium swallow (p 0.019), and (2) response to preoperative radiochemotherapy (p 0.042). These two variables were equally allocated among histologic subtypes. Fig 1. Deviation of the esophagus on the barium swallow. Deviation of the virtual axis representing the middle of the esophageal canal. Groups Three groups were constructed with two variables which were identified as predictive of R0 resection by multivariate analysis: (1) esophageal deviation on barium swallow and (2) response to preoperative radiochemotherapy (Fig 3). The first group was composed of 253 patients without axial deviation of the esophagus on barium swallow with or without preoperative radiochemotherapy, irrespective of tumor response to treatment. The second group was composed of 66 patients with axial deviation of the Thirty-three patients (8.9%) had anastomotic leaks that were observed clinically or by radiology. Respiratory complications were observed in 95 patients (25.5%). Type of Resection According to the 1993 UICC criteria, macroscopically and microscopically R0 resection was achieved in 304 patients (81.7%), R1 resection (histologic evidence of invasion of the section margin or lateral clearance) was achieved in 28 patients (7.5%), and R2 resection (macroscopic residual tumor after surgery) was achieved in 40 patients (10.8%). We assigned patients to two groups for analysis of factors predictive of complete resection: R0, patients who had complete R0 resection (n 304; 81.7%); R1-R2, patients who had incomplete R1 or R2 resection (n 68; 18.3%). Actuarial Survival The actuarial survival is shown in Figure 2. Follow-up was complete for all patients. The mean (sd) follow-up Fig 2. Actuarial survival for the entire population and of group R0 and group R1 and R2 (p 0.001). The number of subjects at risk at each interval is shown in the table at the bottom of the graph.
5 1724 MARIETTE ET AL Ann Thorac Surg ESOPHAGEAL CANCER RESECTION 2003;75: Table 2. Univariate Analysis: Factors Influencing Type of Resection Variables Group R 0 n (%) Group R1 R2 n (%) 2 p Age 60 y y Gender Male Female 32 8 Malnutrition a No Yes Dysphagia No Yes Distance T-MA b 25 cm cm Esophageal deviation on barium swallow No Yes Tumor height 10 cm cm Tumor diameter on computed tomography 30 mm mm Lymph node invasion on computed tomography No Yes T (endoscopic ultrasonography [us]) Us T1 T Us T N (endoscopic ultrasonography) Us N Us N Histologic type Squamous cell Adenocarcinoma Other 8 2 Tumor differentiation Moderate to well Poor or none Treatment Surgery alone Neoadjuvant radiochemotherapy Response to radiochemotherapy Complete or partial Stability or progression 17 8 Type of resection With thoracotomy Without thoracotomy a Malnutrition: 10% weight loss; b distance T-MA is the distance between the upper pole of the tumor and the mandibular arcades. esophagus on barium swallow who responded totally or partially to preoperative radiochemotherapy. The third group was composed of 53 patients with esophageal deviation who either did not respond to preoperative radiochemotherapy or were not given preoperative adjuvant therapy. Rates of R0 resection (Table 4) and survival (Fig 4) were significantly different between groups (p 0.001) and two-by-two (p 0.013). Comment Pre-therapeutic exploration of patients with esophageal cancer is hampered by difficulty determining the potential for curative resection before histologic examination of the surgical specimen [8]. In fact, the survival rates of noncurative surgery are essentially identical to those achieved with nonsurgical therapy using combined che-
6 Ann Thorac Surg MARIETTE ET AL 2003;75: ESOPHAGEAL CANCER RESECTION Table 3. Multivariate Analysis: Preoperative Factors Predictive of Complete Resection (RO) Variables p 2 Ratio Odds- 95% Confidence Interval Esophageal deviation on barium swallow No Yes 1.0 Response to neoadjuvant radiochemotherapy Complete or partial Stability or progression GENERAL THORACIC Fig 3. Group constitution according to the two factors predictive of complete resection: esophageal axis deviation on barium swallow and morphologic response to preoperative radiochemotherapy (RCT). moradiation [9]. Consequently, surgery can be retained as a valid option for patients with esophageal cancer, with the goal of improved 5-year survival only if R0 resection can be achieved [1 4]. This requirement was confirmed in our series of 372 patients in which median survival was 54.9 months in the R0 group and 10.8 months in the R1 and R2 group. The 5-year survival rates were 47% and 4% (p 0.001), respectively. In a modern series [3, 4, 10 13], 5-year survival rates after curative surgery in esophageal cancer ranged from 23% to 55%, including series with three-field lymph node dissection. Long-term survival has clearly improved since 1980, because of advances in surgical and anesthetic techniques, together with improvements in perioperative management, tumoral staging, and adjuvant therapy. Nevertheless, 5-year survival remains low. In order to establish what elements of the pretherapeutic workup enable identifying a population of patients who can benefit from surgical resection, we identified two preoperative variables predictive of R0 resection: (1) complete or partial response to preoperative radiochemotherapy and (2) absence of esophageal deviation on the barium swallow. Objective response to neoadjuvant radiochemotherapy [14, 15] or chemotherapy [16, 17] has been associated with better survival for patients with resectable esophageal carcinoma. Inversely, others have not demonstrated better survival with neoadjuvant radiochemotherapy [18, 19] or chemotherapy [20, 21]. Phase II trials have demonstrated that 20% to 40% of patients given preoperative radiochemotherapy achieve complete histologic response [22, 23]. Patients treated with surgery alone were more likely to have an esophageal resection, but those treated with chemotherapy and surgery were more likely to have R0 resection [16, 20]. Work by the French Federation of Digestive Tract Cancerology [15] demonstrated that clinical response, assessed by the World Health Organization radioendoscopic criteria, is overestimated in 10% of patients and underestimated in 29% compared with histologic response. This discordance between clinical and histologic response is well known, the predictive value of negative endoscopic biopsy for diagnosis of complete response is 21% to 47% [24]. Thus, new tools are necessary to assess the efficacy of nonsurgical treatments for esophageal cancers. Deviation of the esophageal axis on the barium swallow is associated with noncurative resection [5, 6], and it is also predictive of extension to neighboring organs [5]. The deviation of the esophageal axis is usually a typical sign of advanced squamous cell carcinoma and is rare in Barrett cancer. In our study, axis deviation was equally allocated among both histologic subtypes and only a few specimens showed Barrett mucosa. An explanation could be the importance of pt3 stage patients (57%) with adenocarcinoma. Surgical resection of esophageal cancer should only be undertaken to attempt curative treatment. The limitations of preoperative explorations to predict tumor resectability require considering other factors predictive of R0 resection. Using two variables predictive of R0 resection (ie, deviation of the esophageal axis on barium swallow and response to neoadjuvant radiochemo- Table 4. Rate of Complete Resection and Survival in the 3 Groups Identified With Multivariate Analysis Group Patients Complete Resection (R0) Median Survival Survival Rate (%) N % N % Months 1 Year 3 Years 5 Years Group 1: no deviation of the esophagus on barium swallow; group 2: deviation of the esophagus on barium swallow and partial or complete response to preoperative radiochemotherapy; and Group 3: deviation of the esophagus on barium swallow and either no response to radiochemotherapy or no preoperative treatment.
7 1726 MARIETTE ET AL Ann Thorac Surg ESOPHAGEAL CANCER RESECTION 2003;75: Fig 4. Survival by the two factors predictive of complete resection. Group 1: no deviation of the esophagus on barium swallow; group 2: deviation of the esophagus on barium swallow and partial or complete response to preoperative radiochemotherapy; group 3: deviation of the esophagus on barium swallow and either no response to radiochemotherapy or no preoperative treatment (p less than between all groups and p less than when compared individually). The number of subjects at risk at each interval is shown in the table at the bottom of the graph. therapy), enabled us to identify three groups of patients with significantly different rates of R0 resection. These two variables are available for all patients at the onset of therapeutic management allowing easy classification of the patients into three groups. For patients with 50% risk of R1 or R2 resection (group 3), we recommend preoperative radiochemotherapy for those with axis deviation on barium swallow, and in patients with no response, only palliation. Further oncology research are necessary to refine the patient selection. References 1. Mriette C, Castel B, Toursel H, Fabre S, Balon JM, Triboulet JP. Surgical management of and long-term survival after adenocarcinoma of the cardia. Br J Surg 2002;89: Mariette C, Maurel A, Fabre S, Balon JM, Triboulet JP. Preoperative prognostic factors for squamous cell carcinomas of the thoracic esophagus. Gastroenterol Clin Biol 2001;25: Orringer MB, Marshall B, Iannettoni MD. Transhiatal esophagectomy: clinical experience and refinements. Ann Surg 1999;230: Karl RC, Schreiber R, Boulware D, Baker S, Coppola D. Factors affecting morbidity, mortality, and survival in patients undergoing Ivor Lewis esophagogastrectomy. Ann Surg 2000;231: Sugimachi K, Watanabe M, Sadanaga N, et al. Pre-operative estimation of complete resection for patients with oesophageal carcinoma. Surg Oncol 1994;3: Mariette C, Fabre S, Balon JM, Finzi L, Triboulet JP. Factors predictive of complete resection of operable esophageal cancer: review of 746 patients. Gastroenterol Clin Biol 2002; 26: Sobon LH, Wittekind C, eds. UICC TNM Classification of Malignant Tumors, 5th ed. New York: Wiley-Liss, Matsubara T, Ueda M, Kokudo N, Takahashi T, Muto T, Yanagisawa A. Role of esophagectomy in treatment of esophageal carcinoma with clinical evidence of adjacent organ invasion. World J Surg 2001;25: Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326: Visbal AL, Allen MS, Miller DL, Deschamps C, Trastek VF, Pairolero PC. Ivor Lewis esophagogastrectomy for esophageal cancer. Ann Thorac Surg 2001;71: Swanson SJ, Batirel HF, Bueno R, et al. Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma. Ann Thorac Surg 2001;72: Elias D, Lasser P, Hatchouel JM, et al. A multivariate prospective study of prognostic factors in 200 operated epidermoid cancers of the esophagus. Definition of patients for whom surgical resection was of benefit. Gastroenterol Clin Biol 1993;17: Nozoe T, Saeki H, Ohga T, Sugimachi K. Clinicopathologic characteristics of esophageal squamous cell carcinoma in younger patients. Ann Thorac Surg 2001;72: Le Prise E, Etienne PL, Meunier B, et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 1994;73: Bedenne L, Seitz JF, Milan C, et al. Cisplatin, 5-FU, and preoperative radiotherapy in esophageal epidermoid cancer. Multicenter phase II FFCD 8804 study. Gastroenterol Clin Biol 1998;22: Medical Research Council Oesophageal Cancer Working Party. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359: Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 200;91: Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997;337: Entwistle JW 3rd, Goldberg M. Multimodality therapy for resectable cancer of the thoracic esophagus. Ann Thorac Surg 2002;73: Urschel JD, Vasan H, Blewett CJ. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2002;183: Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339: Forastiere AA, Orringer MB, Perez-Tamayo C, Urba SG, Zahurak M. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. J Clin Oncol 1993;11: Fink U, Stein HJ, Bochtler H, Roder JD, Wilke HJ, Siewert JR. Neoadjuvant therapy for squamous cell esophageal carcinoma. Ann Oncol 1994;5(Suppl 3): Bates BA, Detterbeck FC, Bernard SA, Qaqish BF, Tepper JE. Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. J Clin Oncol 1996;14:
Pattern of Recurrence Following Complete Resection of Esophageal Carcinoma and Factors Predictive of Recurrent Disease
1616 Pattern of Recurrence Following Complete Resection of Esophageal Carcinoma and Factors Predictive of Recurrent Disease Christophe Mariette, M.D. 1,2 Jean-Michel Balon, M.D. 1 Guillaune Piessen, M.D.
More informationSETTING Fudan University Shanghai Cancer Center. RESPONSIBLE PARTY Haiquan Chen MD.
OFFICIAL TITLE A Phase Ⅲ Study of Left Side Thoracotomy Approach (SweetProcedure) Versus Right Side Thoracotomy Plus Midline Laparotomy Approach (Ivor-Lewis Procedure) Esophagectomy in Middle or Lower
More informationCase Scenario 1. The patient has now completed his neoadjuvant chemoradiation and has been cleared for surgery.
Case Scenario 1 July 10, 2010 A 67-year-old male with squamous cell carcinoma of the mid thoracic esophagus presents for surgical resection. The patient has completed preoperative chemoradiation. This
More informationAlthough esophagectomy remains the standard of care for esophageal
Keresztes et al General Thoracic Surgery Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: Results of a phase II trial R. S. Keresztes, MD J. L. Port, MD M. W. Pasmantier,
More informationA Proposed Strategy for Treatment of Superficial Carcinoma. in the Thoracic Esophagus Based on an Analysis. of Lymph Node Metastasis
Kitakanto Med J 2002 ; 52 : 189-193 189 A Proposed Strategy for Treatment of Superficial Carcinoma in the Thoracic Esophagus Based on an Analysis of Lymph Node Metastasis Susumu Kawate,' Susumu Ohwada,'
More informationThe incidence of adenocarcinoma of the esophagus
GENERAL THORACIC A Retrospective Analysis of Locally Advanced Esophageal Cancer Patients Treated With Neoadjuvant Chemoradiation Therapy Followed by or Alone Kenneth A. Kesler, MD, Paul R. Helft, MD, Elizabeth
More informationTumours of the Oesophagus & Gastro-Oesophageal Junction Histopathology Reporting Proforma
Tumours of the Oesophagus & Gastro-Oesophageal Junction Histopathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.01). S1.01 Identification Family name Given
More informationClinicopathologic and prognostic factors of young and elderly patients with esophageal adenocarcinoma: is there really a difference?
Diseases of the Esophagus (2008) 21, 596 600 DOI: 10.1111/j.1442-2050.2008.00817.x Original article Clinicopathologic and prognostic factors of young and elderly patients with esophageal adenocarcinoma:
More informationSurgical strategies in esophageal cancer
Gastro-Conference Berlin 2005 October 1-2, 2005 Surgical strategies in esophageal cancer J. Rüdiger Siewert Department of Surgery, Klinikum rechts der Isar Technische Universität München Esophageal Cancer
More informationControversies in management of squamous esophageal cancer
2015.06.12 12.47.48 Page 4(1) IS-1 Controversies in management of squamous esophageal cancer C S Pramesh Thoracic Surgery, Department of Surgical Oncology, Tata Memorial Centre, India In Asia, squamous
More informationThe Learning Curve for Minimally Invasive Esophagectomy
The Learning Curve for Minimally Invasive Esophagectomy AATS Focus on Thoracic Surgery Mastering Surgical Innovation Las Vegas Nevada Oct. 27-28 2017 Scott J Swanson, M.D. Professor of Surgery Harvard
More informationAliu Sanni MD SUNY Downstate Medical Center August 16, 2012
Aliu Sanni MD SUNY Downstate Medical Center August 16, 2012 Case Presentation 60yr old AAF with PMH of CAD s/p PCI 1983, CVA, GERD, HTN presented with retrosternal chest pain on 06/12 Associated dysphagia
More informationGastric Cancer Histopathology Reporting Proforma
Gastric Cancer Histopathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.01). S1.01 Identification Family name Given name(s) Date of birth Sex Male Female Intersex/indeterminate
More informationManagement of Esophageal Cancer: Evidence Based Review of Current Guidelines. Madhuri Rao, MD PGY-5 SUNY Downstate Medical Center
Management of Esophageal Cancer: Evidence Based Review of Current Guidelines Madhuri Rao, MD PGY-5 SUNY Downstate Medical Center Case Presentation 68 y/o male PMH: NIDDM, HTN, hyperlipidemia, CAD s/p stents,
More informationImaging in gastric cancer
Imaging in gastric cancer Gastric cancer remains a deadly disease because of late diagnosis. Adenocarcinoma represents 90% of malignant tumors. Diagnosis is based on endoscopic examination with biopsies.
More informationLymph node invasion might have more prognostic impact than R status in advanced esophageal adenocarcinoma
The American Journal of Surgery (2013) 205, 711-717 Clinical Surgery Lymph node invasion might have more prognostic impact than R status in advanced esophageal adenocarcinoma Magali Cabau, M.D. a, Guillaume
More information7/20/2017. Esophageal Cancer: A Less Common But Deadly Cancer. Objectives. Disclosure Statement NYNPA Conference October Saratoga New York
Esophageal Cancer: A Less Common But Deadly Cancer 2017 NYNPA Conference October 18-22 Saratoga New York Mary McGreal DNP, RN, ANP-C, CCRN, CMC, Adjunct Professor at Stony Brook University School of Nursing
More informationEsophageal cancer is a significant health hazard for
Postoperative Radiotherapy Improved Survival of Poor Prognostic Squamous Cell Carcinoma Esophagus GENERAL THORACIC Junqiang Chen, MD, Ji Zhu, MD, Jianji Pan, MD, Kunshou Zhu, MD, Xiongwei Zheng, MD, Mingqiang
More informationMinimally Invasive Esophagectomy- Valuable. Jayer Chung, MD University of Colorado Health Sciences Center December 11, 2006
Minimally Invasive Esophagectomy- Valuable Jayer Chung, MD University of Colorado Health Sciences Center December 11, 2006 Overview Esophageal carcinoma What is minimally invasive esophagectomy (MIE)?
More informationDetermining the Optimal Surgical Approach to Esophageal Cancer
Determining the Optimal Surgical Approach to Esophageal Cancer Amit Bhargava, MD Attending Thoracic Surgeon Department of Cardiovascular and Thoracic Surgery Open Esophagectomy versus Minimally Invasive
More informationCase Scenario year-old white male presented to personal physician with dyspepsia with reflux.
Case Scenario 1 57-year-old white male presented to personal physician with dyspepsia with reflux. 7/12 EGD: In the gastroesophageal junction we found an exophytic tumor. The tumor occupies approximately
More informationEsophageal cancer: Biology, natural history, staging and therapeutic options
EGEUS 2nd Meeting Esophageal cancer: Biology, natural history, staging and therapeutic options Michael Bau Mortensen MD, Ph.D. Associate Professor of Surgery Centre for Surgical Ultrasound, Upper GI Section,
More informationLimited en bloc Resection of the Gastroesophageal Junction with Isoperistaltic Jejunal Interposition
22 Limited en bloc Resection of the Gastroesophageal Junction with Isoperistaltic Jejunal Interposition J.R. Izbicki, W.T. Knoefel, D. C. Broering ] Indications Severe dysplasia in the distal esophagus
More informationOCCULT CERVICAL NODAL METASTASIS IN ESOPHAGEAL CANCER: PRELIMINARY RESULTS OF THREE-FIELD LYMPHADENECTOMY
OCCULT CERVICAL NODAL METASTASIS IN ESOPHAGEAL CANCER: PRELIMINARY RESULTS OF THREE-FIELD LYMPHADENECTOMY Nasser K. Altorki, MD David B. Skinner, MD The extent of lymphadenectomy for carcinoma of the thoracic
More informationCHEMOTHERAPY FOLLOWED BY SURGERY VS. SURGERY ALONE FOR LOCALIZED ESOPHAGEAL CANCER
CHEMOTHERAPY FOLLOWED BY VS. ALONE FOR LOCALIZED ESOPHAGEAL CANCER CHEMOTHERAPY FOLLOWED BY COMPARED WITH ALONE FOR LOCALIZED ESOPHAGEAL CANCER DAVID P. KELSEN, M.D., ROBERT GINSBERG, M.D., THOMAS F. PAJAK,
More informationGreater Manchester & Cheshire Guidelines for Pathology Reporting for Oesophageal and Gastric Malignancy
Greater Manchester & Cheshire Guidelines for Pathology Reporting for Oesophageal and Gastric Malignancy Authors: Dr Gordon Armstrong, Dr Sue Pritchard 1. General Comments 1.1 Cancer reporting: Biopsies
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More informationSurgical Problems in Proximal GI Cancer Management Cardia Tumours Question #1: What are cardia tumours?
Surgical Problems in Proximal GI Cancer Management Cardia Tumours Question #1: What are cardia tumours? Question #2: How are cardia tumours managed? Michael F. Humer December 3, 2005 Vancouver, BC Case
More informationEsophageal carcinoma is one of the most tedious
Subcarinal Node Metastasis in Thoracic Esophageal Squamous Cell Carcinoma Jingeng Liu, MD,* YiHu,MD,* Xuan Xie, MD, and Jianhua Fu, MD Department of Thoracic Oncology, Cancer Center, Sun Yat-sen University,
More informationAbstracting Upper GI Cancer Incidence and Treatment Data Quiz 1 Multiple Primary and Histologies Case 1 Final Pathology:
Abstracting Upper GI Cancer Incidence and Treatment Data Quiz 1 Multiple Primary and Histologies Case 1 A 74 year old male with a history of GERD presents complaining of dysphagia. An esophagogastroduodenoscopy
More informationESOPHAGEAL CANCER. Dr. Paul Gardiner December 17, 2002 Discipline of Surgery Rounds
ESOPHAGEAL CANCER Dr. Paul Gardiner December 17, 2002 Discipline of Surgery Rounds ESOPHAGEAL CANCER I. EPIDEMIOLOGY INCIDENCE, DIAGNOSIS & STAGING II. TREATMENT OPTIONS Current role of induction therapies
More informationEsophageal Cancer Staging Essentials: The New TNM Staging System (7th edition) and Clinicoradiologic Implications
Esophageal Cancer Staging Essentials: The New TNM Staging System (7th edition) and Clinicoradiologic Implications Poster No.: E-0060 Congress: ESTI 2012 Type: Scientific Exhibit Authors: K. Lee, T. J.
More informationCOLLECTING CANCER DATA: STOMACH AND ESOPHAGUS
COLLECTING CANCER DATA: STOMACH AND ESOPHAGUS 2017 2018 NAACCR WEBINAR SERIES Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationLymph node metastasis is one of the most important prognostic
ORIGINAL ARTICLE Comparison of Survival and Recurrence Pattern Between Two-Field and Three-Field Lymph Node Dissections for Upper Thoracic Esophageal Squamous Cell Carcinoma Young Mog Shim, MD, Hong Kwan
More informationHong Kong Society of Upper Gastrointestinal Surgeons CLINICAL MEETING 29 NOV 2012
Hong Kong Society of Upper Gastrointestinal Surgeons CLINICAL MEETING 29 NOV 2012 Esophageal Leiomyoma Introduction Case presentation Operative video Discussion Esophageal Leiomyoma Benign tumors of the
More informationDi Lu 1#, Xiguang Liu 1#, Mei Li 1#, Siyang Feng 1#, Xiaoying Dong 1, Xuezhou Yu 2, Hua Wu 1, Gang Xiong 1, Ruijun Cai 1, Guoxin Li 3, Kaican Cai 1
Case Report Three-port mediastino-laparoscopic esophagectomy (TPMLE) for an 81-year-old female with early-staged esophageal cancer: a case report of combining single-port mediastinoscopic esophagectomy
More information1. Epidemiology of Esophageal Cancer 2. Operative Strategies 3. Minimally Invasive Esophagectomy 4. Video
Minimally Invasive Esophagectomy Guilherme M Campos, MD, FACS Assistant Professor of Surgery Director G.I. Motility Center Director Bariatric Surgery Program University of California San Francisco ESOPHAGEAL
More informationNewly Diagnosed Cases Cancer Related Death NCI 2006 Data
Multi-Disciplinary Management of Esophageal Cancer: Surgical and Medical Steps Forward Alarming Thoracic Twin Towers 200000 150000 UCSF UCD Thoracic Oncology Conference November 21, 2009 100000 50000 0
More informationTranshiatal Esophagectomy: Lower Mortality, Diminished Morbidity, Equal Effectiveness
Transhiatal Esophagectomy: Lower Mortality, Diminished Morbidity, Equal Effectiveness Sunil Malhotra, M.D. Department of Surgery University of Colorado Resident Debate April 30, 2007 Esophageal Cancer
More informationMinimally Invasive Esophagectomy: OVERRATED!!! Sagar Damle UCHSC December 11, 2006
Minimally Invasive Esophagectomy: OVERRATED!!! Sagar Damle UCHSC December 11, 2006 Esophageal Cancer - Est. 15,000 cases in 2006 - Est. 14,000 deaths - Overall 5-year survival: 15.6% - 33.6 % for local
More informationQuiz Adenocarcinoma of the distal stomach has been increasing in the last 20 years. a. True b. False
Quiz 1 1. Which of the following are risk factors for esophagus cancer. a. Obesity b. Gastroesophageal reflux c. Smoking and Alcohol d. All of the above 2. Adenocarcinoma of the distal stomach has been
More informationClinical study on postoperative recurrence in patients with pn0 esophageal squamous cell carcinoma
Guo et al. Journal of Cardiothoracic Surgery 2014, 9:150 RESEARCH ARTICLE Open Access Clinical study on postoperative recurrence in patients with pn0 esophageal squamous cell carcinoma Xu-feng Guo, Teng
More informationClinicopathological Characteristics and Outcome Indicators of Stage II Gastric Cancer According to the Japanese Classification of Gastric Cancer
Clinicopathological Characteristics and Outcome Indicators of Stage II Gastric Cancer According to the Japanese Classification of Gastric Cancer HITOSHI OJIMA 1, KEN-ICHIRO ARAKI 1, TOSHIHIDE KATO 1, KAORI
More informationGastric Cancer Staging AJCC eighth edition. Duncan McLeod Westmead Hospital, NSW
Gastric Cancer Staging AJCC eighth edition Duncan McLeod Westmead Hospital, NSW Summary of changes New clinical stage prognostic groups, ctnm Postneoadjuvant therapy pathologic stage groupings, yptnm -
More informationTowards a more personalized approach in the treatment of esophageal cancer focusing on predictive factors in response to chemoradiation Wang, Da
University of Groningen Towards a more personalized approach in the treatment of esophageal cancer focusing on predictive factors in response to chemoradiation Wang, Da IMPORTANT NOTE: You are advised
More informationXiang Hu*, Liang Cao*, Yi Yu. Introduction
Original Article Prognostic prediction in gastric cancer patients without serosal invasion: comparative study between UICC 7 th edition and JCGS 13 th edition N-classification systems Xiang Hu*, Liang
More informationSignificance of the lymph nodes in the 7th station in rational dissection for metastasis of distal gastric cancer with different T categories
Original Article Significance of the lymph nodes in the 7th station in rational dissection for metastasis of distal gastric cancer with different T categories Wu Song, Yulong He, Shaochuan Wang, Weiling
More informationLYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG
LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi
More informationORIGINAL ARTICLE. aggressive disease with a poor prognosis. Its incidence in the United States has been increasing;
Neoadjuvant Chemoradiotherapy for Esophageal Cancer Is It Worthwhile? ORIGINAL ARTICLE Wael Z. Tamim, MD; Robert S. Davidson, MD; Robert M. Quinlan, MD; Michael A. O Shea, MB, BCh; Richard K. Orr, MD;
More informationMEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER
MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Hideki Akamatsu, MD a Yuzo
More informationRisk factors for lymph node metastasis in histologically poorly differentiated type early gastric cancer
498 Original article Risk factors for lymph node metastasis in histologically poorly differentiated type early gastric cancer Authors C. Kunisaki 1, M. Takahashi 2, Y. Nagahori 3, T. Fukushima 3, H. Makino
More informationEsophageal Cancer. Wesley A. Papenfuss MD FACS Surgical Oncology Aurora Cancer Care. David Demos MD Thoracic Surgery Aurora Cancer Care
Esophageal Cancer Wesley A. Papenfuss MD FACS Surgical Oncology Aurora Cancer Care David Demos MD Thoracic Surgery Aurora Cancer Care No Disclosures Learning Objectives Review the classification scheme
More informationLya Crichlow, MD Kings County Hospital Center September 3, 2009 Morbidity and Mortality Conference Case presentation 56 year old male who presented with 1 week history of dysphagia Unable to tolerate solids
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationThe prognosis for patients with esophageal cancer is poor.
ORIGINAL ARTICLE A Phase II Study of Paclitaxel, Carboplatin, and Radiation with or without Surgery for Esophageal Cancer Henry Wang, MD, Janice Ryu, MD, David Gandara, MD, Richard J. Bold, MD, Shiro Urayama,
More informationAdenocarcinoma of gastro-esophageal junction - Case report
Case Report denocarcinoma of gastro-esophageal junction - Case report nupsingh Dhakre 1*, Ibethoi Yengkhom 2, Harshin Nagori 1, nup Kurele 1, Shreedevi. Patel 3 1 2 nd year Resident, 2 3rd year Resident,
More informationOncologist. The. Multimodality Therapy for Esophageal Cancer J.R. SIEWERT, H.J. STEIN, U. FINK ABSTRACT. Meet The Professor
The Oncologist Meet The Professor Multimodality Therapy for Esophageal Cancer J.R. SIEWERT, H.J. STEIN, U. FINK Chirurgische Klinik und Poliklinik, Klinikum rechts der Isar der TU München, München, Germany
More informationPrognostic factors in patients with thoracic esophageal carcinoma staged pt 1-4a N 0 M 0 undergone esophagectomy with three-field lymphadenectomy
Original Article Page 1 of 7 Prognostic factors in patients with thoracic esophageal carcinoma staged pt 1-4a N 0 M 0 undergone esophagectomy with three-field lymphadenectomy Xiaohui Chen 1, Junqiang Chen
More informationDetermining the optimal number of lymph nodes harvested during esophagectomy
Original Article Determining the optimal number of lymph nodes harvested during esophagectomy Khaldoun Almhanna, Jill Weber, Ravi Shridhar, Sarah Hoffe, Jonathan Strosberg, Kenneth Meredith Department
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationLog odds of positive lymph nodes is a novel prognostic indicator for advanced ESCC after surgical resection
Original Article Log odds of positive lymph nodes is a novel prognostic indicator for advanced ESCC after surgical resection Mingjian Yang 1,2, Hongdian Zhang 1,2, Zhao Ma 1,2, Lei Gong 1,2, Chuangui Chen
More informationClinical Aspects of Multimodality Therapy for Resectable Locoregional Esophageal Cancer
Review Clinical Aspects of Multimodality Therapy for Resectable Locoregiol Esophageal Cancer Masayuki Shinoda, MD, Shunzo Hatooka, MD, Shoichi Mori, MD, and Tetsuya Mitsudomi, MD Radical resection has
More informationExtended multi-organ resection for ct4 gastric carcinoma: A retrospective analysis
Original Article Extended multi-organ resection for ct4 gastric carcinoma: A retrospective analysis 1. Longbin Xiao, 2. Mingzhe Li, 3. Fengfeng Xu, Department of General Surgery I, 4. Huishao Ye, Department
More informationCharacteristics of intramural metastasis in gastric cancer. Tatsuya Hashimoto Kuniyoshi Arai Yuichi Yamashita Yoshiaki Iwasaki Tsunekazu
ORIGINAL ARTICLE Characteristics of intramural metastasis in gastric cancer Tatsuya Hashimoto Kuniyoshi Arai Yuichi Yamashita Yoshiaki Iwasaki Tsunekazu Hishima Author for correspondence: T. Hashimoto
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationImpact of esophageal cancer staging on overall survival and disease-free survival based on the 2010 AJCC classification by lymph nodes
Journal of Radiation Research, 2013, 54, 307 314 doi: 10.1093/jrr/rrs096 Advance Access Publication 2 November 2012 Impact of esophageal cancer staging on overall survival and disease-free survival based
More informationThe present staging system for esophageal carcinoma
Esophageal Carcinoma: Depth of Tumor Invasion Is Predictive of Regional Lymph Node Status Thomas W. Rice, MD, Gregory Zuccaro, Jr, MD, David J. Adelstein, MD, Lisa A. Rybicki, MS, Eugene H. Blackstone,
More informationEvaluation of the 7 th edition of the UICC-AJCC tumor, node, metastasis classification for esophageal cancer in a Chinese cohort
Original Article Evaluation of the 7 th edition of the UICC-AJCC tumor, node, metastasis classification for esophageal cancer in a Chinese cohort Yan Huang 1 *, Weigang Guo 2 *, Shiming Shi 1, Jian He
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationCharacteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Mei Li & Zhi-xiong Lin Department of Radiation
More informationThe incidence of esophageal carcinoma has increased
The Best Operation for Esophageal Cancer? Arjun Pennathur, MD, Jie Zhang, MD, Haiquan Chen, MD, and James D. Luketich, MD Heart, Lung, and Esophageal Surgery Institute, University of Pittsburgh Medical
More informationOverall survival analysis of neoadjuvant chemoradiotherapy and esophagectomy for esophageal cancer
Original Article Overall survival analysis of neoadjuvant chemoradiotherapy and esophagectomy for esophageal cancer Faisal A. Siddiqui 1, Katelyn M. Atkins 2, Brian S. Diggs 3, Charles R. Thomas Jr 1,
More informationGastroesophageal reflux disease Principles of GERD treatment Treatment of reflux diseases GERD
Esophagus Anatomy/Physiology Gastroesophageal reflux disease Principles of GERD treatment Treatment of reflux diseases GERD Manometry Question 50 years old female with chest pain and dysphagia. Manometry
More informationAATS Focus on Thoracic Surgery: Minimally Invasive Esophagectomy: Are We Still Getting Better in 2017?
AATS Focus on Thoracic Surgery: Mastering Surgical Innovation Las Vegas, NV October 28, 2017 Session VIII: Video Session Minimally Invasive Esophagectomy: Are We Still Getting Better in 2017? James D.
More informationIn most Western countries, esophageal adenocarcinoma
Nodal Metastasis and Sites of Recurrence After En Bloc Esophagectomy for Adenocarcinoma Geoffrey W. B. Clark, FRCS(Ed), Jeffrey H. Peters, MD, Adrian P. Ireland, FRCS(I), Afshin Ehsan, BS, Jeffrey A. Hagen,
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationIndex. Surg Oncol Clin N Am 14 (2005) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 14 (2005) 433 439 Index Note: Page numbers of article titles are in boldface type. A Abdominosacral resection, of recurrent rectal cancer, 202 215 Ablative techniques, image-guided,
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adenocarcinoma, pancreatic ductal, laparoscopic distal pancreatectomy for, 61 Adrenal cortical carcinoma, laparoscopic adrenalectomy for, 114
More informationTreatment Strategy for Non-curative Resection of Early Gastric Cancer. Jun Haneg Lee. Sungkyunkwan University, Samsung Medical Center, Seoul Korea
Treatment Strategy for Non-curative Resection of Early Gastric Cancer Jun Haneg Lee. Sungkyunkwan University, Samsung Medical Center, Seoul Korea Classic EMR/ESD data analysis style Endoscopic resection
More informationdoi: /j.ijrobp
doi:10.1016/j.ijrobp.2010.08.037 Int. J. Radiation Oncology Biol. Phys., Vol. 82, No. 1, pp. 475 482, 2012 Copyright Ó 2012 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/$ - see front
More informationRole of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City
Role of Surgery in Management of Non Small Cell Lung Cancer Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City Introduction Surgical approach Principle and type of surgery
More informationResectable locally advanced oesophagogastric cancer
Resectable locally advanced oesophagogastric cancer Clinical Case Discussion Florian Lordick University Cancer Center Leipzig University Clinic Leipzig Leipzig, Germany esmo.org DISCLOSURES Honoraria for
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationDelay in Diagnostic Workup and Treatment of Esophageal Cancer
J Gastrointest Surg (2010) 14:476 483 DOI 10.1007/s11605-009-1109-y ORIGINAL ARTICLE Delay in Diagnostic Workup and Treatment of Esophageal Cancer Brechtje A. Grotenhuis & Pieter van Hagen & Bas P. L.
More informationWen-Bin Shen 1, Hong-Mei Gao 2, Shu-Chai Zhu 1*, You-Mei Li 1, Shu-Guang Li 1 and Jin-Rui Xu 1
Shen et al. World Journal of Surgical Oncology (2017) 15:192 DOI 10.1186/s12957-017-1259-4 RESEARCH Analysis of the causes of failure after radical surgery in patients with P T 3 N 0 M 0 thoracic esophageal
More informationPROPOSED REVISION OF THE STAGING CLASSIFICATION FOR ESOPHAGEAL CANCER
PROPOSED REVISION OF THE STAGING CLASSIFICATION FOR ESOPHAGEAL CANCER Robert J. Korst, MD a Valerie W. Rusch, MD a Ennapadam Venkatraman, PhD b Manjit S. Bains, MD a Michael E. Burt, MD, PhD a Robert J.
More informationHISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018
30 EACTS Annual Meeting Barcelona, Spain 1-5 October 2016 SURGERY FOR TUMORS WITH INVASION OF THE APEX lung cancer of the apex of the chest involving any structure of the apical chest wall irrespective
More informationYuanli Dong 1,2, Hui Guan 1,2, Wei Huang 1, Zicheng Zhang 1, Dongbo Zhao 3, Yang Liu 1,3, Tao Zhou 1, Baosheng Li 1.
Original Article Precise delineation of clinical target volume for crossingsegments thoracic esophageal squamous cell carcinoma based on the pattern of lymph node metastases Yuanli Dong 1,2, Hui Guan 1,2,
More informationLymph node metastasis in gastric cardiac adenocarcinoma in male patients
Online Submissions: http://www.wjgnet.com/esps/ wjg@wjgnet.com doi:10.3748/wjg.v19.i37.6245 World J Gastroenterol 2013 October 7; 19(37): 6245-6257 ISSN 1007-9327 (print) ISSN 2219-2840 (online) 2013 Baishideng.
More informationJ Clin Oncol 22: by American Society of Clinical Oncology INTRODUCTION
VOLUME 22 NUMBER 22 NOVEMBER 15 2004 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Adjuvant Chemotherapy for Resected Adenocarcinoma of the Esophagus, Gastro-Esophageal Junction, and Cardia:
More informationSurgical Management of Esophageal Cancer Sophia L Fu, MD Long Island College Hospital SUNY Downstate Medical Center, Brooklyn, NY 03/27/2009 Questions The T and N status of esophageal carcinoma is most
More informationPrognostic Factors for the Survival of Patients with Esophageal Carcinoma in the U.S.
1434 Prognostic Factors for the Survival of Patients with Esophageal Carcinoma in the U.S. The Importance of Tumor Length and Lymph Node Status Mohamad A. Eloubeidi, M.D., M.H.S. 1,2 Renee Desmond, Ph.D.
More informationDetermining Resectability and Appropriate Surgery for Esophageal Cancer
Determining Resectability and Appropriate Surgery for Esophageal Cancer Peter Baik, DO, FACOS Thoracic Surgery Cancer Treatment Centers of America 1 Esophageal and Esophagogastric Junction Cancers Siewert
More informationOriginal articledote_1350. S. P. Mehta, 1 P. Jose, 1,2 A. Mirza, 3 S. A. Pritchard, 3 J. D. Hayden, 1 and H. I. Grabsch 2
1..7 Diseases of the Esophagus (2012), DOI: 10.1111/j.1442-2050.2012.01350.x Original articledote_1350 Comparison of the prognostic value of the 6th and 7th editions of the Union for International Cancer
More informationIntended for use by Clinicians and Health Care Providers involved in the Management or Referral of adult patients with pancreatic
Intended for use by Clinicians and Health Care Providers involved in the Management or Referral of adult patients with pancreatic cancer Section AA Cancer Centre Referrals In the absence of metastatic
More informationEsophageal cancer located at the cervical and upper thoracic
ORIGINAL ARTICLE Esophageal Cancer Located at the Neck and Upper Thorax Treated with Concurrent Chemoradiation: A Single- Institution Experience Shulian Wang, MD,* Zhongxing Liao, MD, Yuan Chen, MD, Joe
More informationClinicopathologic Characteristics and Prognosis of Gastric Cancer in Young Patients
Yonago Acta medica 2012;55:57 61 Clinicopathologic Characteristics and Prognosis of Gastric Cancer in Young Patients Hiroaki Saito, Seigo Takaya, Yoji Fukumoto, Tomohiro Osaki, Shigeru Tatebe and Masahide
More informationSurgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study
Original article Annals of Gastroenterology (2013) 26, 346-352 Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study Subhankar Chakraborty
More information